A Phase I trial of the farnesyltransferase inhibitor L-778,123 and radiotherapy for locally advanced lung and head and neck cancer.

PURPOSE: Preclinical data have demonstrated that farnesyltransferaseinhibitors (FTIs) are radiation sensitizers in selected cell lines. The objective of this Phase I trial was to determine the maximally tolerated dose of the FTI L-778,123 in combination with radiotherapy in non-small cell lung canc...

Full description

Bibliographic Details
Main Authors:	Hahn, S, Bernhard, E, Regine, W, Mohiuddin, M, Haller, D, Stevenson, J, Smith, D, Pramanik, B, Tepper, J, DeLaney, T, Kiel, K, Morrison, B, Deutsch, P, Muschel, R, Mckenna, W
Format:	Journal article
Language:	English
Published:	2002

A Phase I trial of the farnesyltransferase inhibitor L-778,123 and radiotherapy for locally advanced lung and head and neck cancer.

Similar Items